TRVI - Trevi Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
+0.36 (+4.16%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close8.66
Bid7.30 x 800
Ask10.95 x 800
Day's Range8.66 - 9.23
52 Week Range7.18 - 9.60
Avg. Volume200,078
Market Cap160.302M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-58.45
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire20 days ago

    Trevi Therapeutics Announces Pricing of Initial Public Offering

    Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at an initial public offering price of $10.00 per share, for gross proceeds of $55 million. In addition, Trevi has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares are being offered by Trevi.

  • Benzinga26 days ago

    Trevi Therapeutics IPO: What You Need To Know

    Trevi Therapeutics, Inc. will issue nearly 4.7 million shares on the Nasdaq under ticker TRVI, according to the firm’s S-1 filing. Lead underwriters include SVB Leerink, Stifel and BMO Capital Markets. The Connecticut biotech targets chronic pruritis, chronic cough related to idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia related to Parkinson’s disease.

  • We're sorry this is all we were able to find about this topic.